1. Volume 116, Issue 1, Pages 161-167 (January 1999)
Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects 
Jorge-Luis Poo, Wladimiro Jiménez, Rosa María Muñoz, Marta Bosch-Marcé, Nuria Bordas, Manuel Morales-Ruiz, Manuel Pérez, Ramón Deulofeu, Manuel Solé, Vicente Arroyo, Juan Rodés 
Gastroenterology 
Volume 116, Issue 1, Pages (January 1999)
DOI: /S (99)
Copyright © 1999 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Photomicrographs of the liver from a CCl4-treated rat receiving long-term (A) ETA/ETB-receptor antagonist RO or (B) vehicle. Note the marked architectural distortion leading to fully developed cirrhosis (Masson's trichome staining; original magnification 40×).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

3. Fig. 1
Photomicrographs of the liver from a CCl4-treated rat receiving long-term (A) ETA/ETB-receptor antagonist RO or (B) vehicle. Note the marked architectural distortion leading to fully developed cirrhosis (Masson's trichome staining; original magnification 40×).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

4. Fig. 2
Plasma and hepatic concentrations of ET in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO or vehicle daily for 10 weeks. aP < 0.001, bP < 0.01, cP < 0.05 vs. control rats; dP < 0.05 vs. vehicle.
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

5. Fig. 2
Plasma and hepatic concentrations of ET in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO or vehicle daily for 10 weeks. aP < 0.001, bP < 0.01, cP < 0.05 vs. control rats; dP < 0.05 vs. vehicle.
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

6. Fig. 3
Individual values of MAP in basal conditions and 15 minutes after administration of an intravenous bolus of ET-1 (600 pmol/kg body wt) to (A) control and (B) cirrhotic rats treated long-term with RO (▴) or vehicle (•).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

7. Fig. 3
Individual values of MAP in basal conditions and 15 minutes after administration of an intravenous bolus of ET-1 (600 pmol/kg body wt) to (A) control and (B) cirrhotic rats treated long-term with RO (▴) or vehicle (•).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

8. Fig. 4
Hepatic concentration of hydroxyproline in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO or vehicle daily for 10 weeks. aP < vs. control rats; bP < 0.05 vs. cirrhotic rats receiving vehicle.
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

9. Fig. 5
Representative Northern blot analysis of procollagen type I mRNA in liver tissue of control and cirrhotic rats. Northern blotting was performed with total RNA (15 μg/lane) isolated from the liver. The membrane was probed with an α-32P–labeled 4.1-kb cDNA of human procollagen type I. A picture of the 18S and 28S RNA bands on the formaldehyde/agarose gel is depicted to show equal loading of RNA in all lanes.
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions